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Centre (TSRCC) and two community teaching hospitals - the Toronto 
East General Hospital (TEGH) and The Scarborough Hospital (TSH). 
Methods: TSRCC does not have oncological thoracic surgeons on 
site and many of its thoracic oncology patients receive their surgery at 
TEGH and TSH. Colleagues from these three institutions convened to 
consolidate their services along patient-centered lines and to improve 
access to the specialist lung oncology team. The redesigned service is 
being assessed and continues to be improved. 
Results: A multi-institution (MI), multidisciplinary (MD) lung cancer 
TB is now held weekly at TSRCC and is attended by physicians from 
all 3 sites. Weekly MI/MD clinics also operate at TSRCC and TEGH. 
An average of about 10 patients/wk are discussed at TB, approximately 
55% from TSRCC, 25% TEGH and 20% TSH. TB documentation and 
actual patient management were assessed in 50 patients. 18 (36%) had 
the TB outcome formally documented in the patient chart. Compliance 
with the TB recommendation was 100% in 17 evaluable patients. In the 
11 months before and after the TB began 14 and 32 patients respec-
tively were enrolled on the site group’s highest recruiting trial, a 230% 
increase.
Discussion and Conclusion: A non-hierarchical model with 2-way 
ﬂow of expertise and integration between the RCC and Community 
has been developed to consolidate lung cancer services. This is an 
uncommon organizational paradigm in Canada. The MI-MD TB meets 
a clinical need, plays a part in increasing clinical trial recruitment and 
the high rate of compliance with treatment recommendations suggests 
functionality. Steps to improve TB documentation have been imple-
mented. Ongoing, speciﬁc projects to develop the service include a pro-
spective database to capture details of patient management and the de-
cision-making process and the reorganization of patient care pathways 
for those presenting with locally advanced but potentially curative lung 
cancer. Continuous improvement and collaboration across institutional 
boundaries are needed to deliver accessible, multidisciplinary evidence-
based lung cancer treatment to as many patients as possible.
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Background: The numbers of lung cancer patients in Japan in 2015 are 
estimated to reach 100,000 men and 35,000 women, reaching 2.6 times 
the levels of 1993, and are increasing at a remarkable rate each year, 
with the incidence among the elderly being particularly high. There 
have been sporadic reports of research on depression as an indicator of 
the mental health of ambulatory patients with lung cancer. In addition, 
although alleviation of the fatigue, loss of appetite, nausea and vomit-
ing characteristically observed in cancer patients is important, there 
has been hardly any research conducted on the correlation between 
depression, sleep and nutritional status in ambulatory patients with lung 
cancer. 
Objective: The object of this study was to examine the correlation 
between depression, sleep and nutritional status in ambulatory patients 
with lung cancer. 
Methods: The subjects of this study consisted of 14 patients with lung 
cancer being treated on an outpatient basis at general hospital A in the 
Tohoku region of Japan who were able to communicate verbally, were 
free of cognitive problems, and from whom consent was in this study 
(12 men, 2 women). The survey was conducted using self-adminis-
trated questionnaires. Although the patients were basically asked to ﬁll 
out the questionnaires while they were waiting to be examined, some of 
the patients ﬁlled out the questionnaires at home for personal reasons 
and then returned by mail. The survey parameters used the McCorkle 
Symptom Distress Scale to determine distress symptoms, CES-D ac-
cording to the NIMH for depression, the Pittsburgh Sleep Quality Index 
(PSQI) to evaluate sleeping status, and hematology data (albumin, total 
protein, RBC count and hemoglobin) to assessment nutritional status. 
After calculating descriptive statistics using these variables, partial cor-
relation coefﬁcients were calculated using age for the control variable. 
Results: The age of the subjects ranged from 56 to 84 years and the 
average age was 70.2±8.6 years overall. The average of the symptom 
distress scale was 20.4±4.3. The average for depression was 15.0±8.3, 
and when the cutoff point at which depression is suspected based on 
previous studies conducted in Japan is taken to be a score of 17 or 
higher, this means that there were 5 subjects (35.7%) suspected of suf-
fering from depression. The average for sleep was 4.4±4.6, and there 
were 4 subjects (28.6%) that surpassed the cutoff point of 5.5 or more 
judged to be indicative of sleep disorders. The results for hematology 
data yielded an average albumin value of 3.8±0.4 g/dl, and there were 
10 subjects at or below an albumin level of 4.0 g/dl (71.4%). The aver-
age values for total protein, RBC count and hemoglobin were 6.7±0.5 
g/dl, 3.6±0.7 x 106/μl and 11.6±2.2 g/dl, respectively. Calculation of 
partial correlation coefﬁcients between the variables of depression, 
sleep and nutritional status using age for the control variable revealed a 
signiﬁcant correlation between depression and sleep (r= .717, p= .006). 
Namely, sleep disorders were observed when depression was high. 
In addition, there was also a correlation between albumin and sleep 
disorders (r= .498, p= .083), thus indicating that the greater the sleep 
disorder the poorer the nutritional status of the subject. 
Conclusion: Depression was observed in roughly 40% of ambulatory 
patients with lung cancer, sleep disorders were observed the greater the 
degree of depression, and poor nutritional status was also indicated. In 
addition suggesting the importance of preventing and providing support 
for depression among lung cancer patients, these ﬁndings suggested 
the need to provide support for ensuring that patients sleep soundly in 
order to lead stable daily lives, as well as provide assistance to enable 
them to maintain proper nutritional status. 
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Bone metastases occur in 20% to 40% of patients with lung cancer. Not 
sufﬁcient data exists for the role of bisphosphonates in overall survival 
and time to progression of these patients On the other hand, recent 
studies demonstrate a direct anti-proliferative effect of third-generation 
BPs on lung tumors which may inﬂuence the survival.
In this retrospective study, we examined the clinical impact of BPs, 
with a focus on the survival, time to progression and pain effect in lung 
cancer patients with bone metastases.
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108 lung cancer patients (stage IIIb-IV) were included. 55/108 had 
abnormal bone scan and received BPs (Group A)-zoledronic acid, 8 mg 
i.v. every 21 days- whereas the other 53 patients didn’t receive BPs: 
30/53 with abnormal bone scan (Group B) and 23/53 patients with nor-
mal bone scan (Group C-control group). All patients were treated with 
a combination chemotherapy consisted of taxan plus carboplatin.
Statistical results are shown in the Table below. Compared to Group 
C, Group A had a statistically signiﬁcant longer survival (p=0.015), 
whereas Group B didn’t show any statistical signiﬁcant difference 
in survival compared to Group C (p>0.05). A statistically signiﬁcant 
positive correlation was found between the number of cycles of therapy 
with BPs and total patients’ survival (p<0.01 Pearson correlation) and 
time to progression(p<0.01). Pain effect of BPs didn’t differ signiﬁcant-
ly in both groups of patients with abnormal bone scan (p>0.05).
 Median-Std Error for Survival Time
Group A 433 ± 78
Group B 252 ± 78
Group C 255 ± 87
p 0.004
The addition of BPs seems to increase overall survival in lung cancer 
patients with bone metastases. The longer period of receiving BPs, the 
better effect on survival and time to progression. Further studies are 
needed to support the potential usefulness of BPs as a therapeutic agent 
against lung cancer.
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Background: The multitargeted antifolate and potent TS inhibitor 
pemetrexed compared favorably (similar efﬁcacy, lower toxicity) to 
docetaxel in a large, randomized phase III trial of previously treated 
patients with NSCLC. Preclinical data indicate that overexpression of 
TS correlates with reduced sensitivity to pemetrexed in antifolate-resis-
tant cell lines. A recent study on chemonaive NSCLC patients indicated 
higher TS expression in squamous cell carcinoma than in adenocarci-
noma. These data suggest that patients with adenocarcinoma may have 
greater sensitivity to pemetrexed compared to patients with squamous 
histology. A study to evaluate TS expression in large cell histology is 
currently being planned.  
Methods: This is a retrospective analysis of the large phase III study 
of pemetrexed (500 mg/m2 IV with vitamin B12 injections + oral folic 
acid) vs docetaxel (75 mg/m2 IV) Q 21 days. A statistical test for treat-
ment-by-histology interaction was performed using a Cox model of 
overall survival (OS) with main effects for treatment (pemetrexed vs 
docetaxel) and squamous histology (no vs yes) plus a treatment-by-his-
tology interaction term (non-squamous pemetrexed vs all other). Since 
a potential for imbalances between arms with respect to prognostic 
factors within histologic groups existed, the models were cofactor-
adjusted by including terms for ECOG performance status (PS 0-1 vs 
2), time since prior chemotherapy (≥3 months vs < 3 months), disease 
stage (IIIB vs IV), and gender (female vs male). Subsequent Cox 
models of OS provided estimates of cofactor-adjusted treatment hazard 
ratios (HR) within histologic subgroups. Unadjusted medians within 
histologic subgroups were calculated using the Kaplan-Meier method.    
Results: Treatment-by-histology interaction was statistically signiﬁcant 
(p=.001), indicating that the effect of study treatment on survival varied 
with histology. Medians and hazard ratios by subgroup are presented 
in the table below. In the squamous cell subgroup, patients treated with 
docetaxel had statistically better survival than patients treated with 
pemetrexed (p=.018). However, for each of the non-squamous histolog-
ic subgroups the adjusted HRs numerically favored pemetrexed. When 
combining these into a single non-squamous subgroup, pemetrexed was 
statistically superior to docetaxel (p=.048). 
Histologic Subgroup N Median OS, months Adjusted HR (95% CI)
Squamous Cell:
pemetrexed 78 6.2
docetaxel 94 7.4 1.563 (1.079, 2.264)
Adenocarcinoma:
pemetrexed 158 9.0
docetaxel 144 9.2 0.915 (0.685, 1.224)
Large Cell:
pemetrexed 18 12.8
docetaxel 29 4.5 0.266 (0.112, 0.633)
Other/Indeterminate Histology:
pemetrexed 29 9.4
docetaxel 21 7.9 0.570 (0.270, 1.204)
Combined Non-Squamous:
pemetrexed 205 9.3
docetaxel 194 8.0 0.778 (0.607, 0.997)
Conclusions: The statistically signiﬁcant treatment-by-histology inter-
action indicates that patients with non-squamous histology treated with 
pemetrexed had signiﬁcantly higher survival compared to all others 
on trial. Docetaxel had statistically better survival than pemetrexed in 
the squamous cell subgroup, while pemetrexed had statistically better 
survival than docetaxel in the combined non-squamous subgroup. One 
hypothesis for this observed interaction is that TS overexpression in 
squamous cell carcinoma leads to reduced sens
